Headquartered in Liège (Belgium), Xpress Biologics is a leading biotech company developing expression systems and manufacturing processes for the production of protein therapeutics and plasmid DNA, one of the most in-demand starting material for the production of Advanced Therapy Medicinal Products. 

Founded in 2014 by three former employees of Eurogentec, Xpress Biologics has built a strong competitive positioning in the market in the time-effective production of high-purity plasmid DNA. Xpress Biologics serves as a one-stop shop for customers in the preclinical and early clinical development stages. With ArchiMed’s support, Xpress Biologics will reinforce their GMP capabilities and increase the capacity available for production for late clinical and commercial product. 

  • Investment date

    2021

  • Sector

    Biopharma

  • Transaction type

    Buy-Out

  • Growth theme

    Manufacturing capacity expansion / Internationalization

  • Location

    Belgium